Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

May 14, 2009

Oncolytics Biotech(R) Inc.’s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference

May 12, 2009

Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study

May 5, 2009

Oncolytics Biotech(R) Inc. Announces 2009 First Quarter Results

February 5, 2009

Media Advisory – Oncolytics Biotech(R) Inc. to Present at BioPartnering North America

February 4, 2009

Cancer Therapy & Research Center at The University of Texas Health Science Center and Oncolytics Biotech(R) Inc. Announce Multi-Trial Clinical Research Collaboration

January 27, 2009

Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer

January 13, 2009

Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent

December 22, 2008

Oncolytics Biotech Inc. Appoints Dr. Matt Coffey as Chief Operating Officer

December 18, 2008

Oncolytics Biotech Inc. Completes Patient Enrolment in Two U.K. REOLYSIN(R) Combination Therapy Clinical Trials

December 18, 2008

Oncolytics Biotech Inc. Amends Terms of Previously Issued Broker Warrants

Page 58 of 69

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.